Sažetak
Uvod/Cilj. Kronova bolest (Crohn's disease – CD) i ulcerozni kolitis (ulcerative colitis – UC) su hronične, idiopatske, zapaljenske bolesti digestivnog trakta. Cilj rada bio je da se utvrdi da li kod bolesnika sa CD i UC postoji uzajamni odnos između kliničkih pokazatelja stepena aktivnosti bolesti i prisustva vancrevnih manifestacija sa patohistološkim stepenom aktivnosti bolesti. Metode. Studija preseka obuhvatila je 134 bolesnika (67 sa CD i 67 sa UC) lečena u Klinici za gastroenterologiju Kliničkog centra Srbije u Beogradu. Nakon kliničke, laboratorijske, endoskopske, patohistološke i radiološke dijagnostike, bolesnici su na osnovu patohistološke aktivnosti bolesti podeljeni u dve grupe. U grupu I svrstano je 79 bolesnika čije su vrednosti petostepenog gradusa patohistološke aktivnosti bile manje od 5 (45 sa CD i 34 sa UC), dok je u grupi II bilo 55 bolesnika sa vrednostima većim od 5 (22 sa CD i 33 sa UC). Za kliničku procenu aktivnosti bolesti korišćen je indeks aktivnosti CD bolesti (CDAI) i Truelove i Wittsova skala za UC. Rezultati. Vancrevne manifestacije CD bile su prisutne kod 28,9% bolesnika grupe I i 63,6% bolesnika grupe II (p < 0,05). Upoređivanjem srednjih vrednosti CDAI uočena je statistički značajna razlika između dve grupe bolesnika (grupa I: 190,0 ± 83,0, grupa II: 263,4 ± 97,6; p < 0,05). Kod bolesnika sa UC nije utvrđena veza između prisustva vancrevnih manifestacija bolesti, Truelove i Wittsove skale i patohistološke aktivnosti bolesti (p > 0,05). Zaključak. Kod bolesnika sa CD prisustvo vancrevnih manifestacija, zajedno sa višim CDAI, ukazuje na veći stepen patohistološke aktivnosti bolesti. Nasuprot tome, kod bolesnika sa UC, Truelove i Wittsova skala i prisustvo vancrevnih manifestacija nisu bili pouzdani prediktori histološkog stepena aktivnosti bolesti.
Ključne reči
Array
Array
Array
Array
Array
Array
Array
Array
Array
Array
Array
Array
Reference
Steinhardt HJ, Loeschke K, Kasper H, Holtermüller KH, Schäfer H. European Cooperative Crohn’s Disease Study (ECCDS): clinical features and natural history. Digestion 1985; 31(2−3): 97−108.
Griffel LH, Das KM. Ulcerative colitis: pathogenesis, diagno-sis, and current treatment. J Assoc Acad Min Phys 1996; 7(3): 63–9.
Van Assche G, Dignass A, Panes J, Beaugerie L, Karagiannis J, Allez M, et al. The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: Definitions and diagnosis. J Crohns Colitis 2010; 4(1): 7−27.
Popović O, Vukčević V. Inflammatory bowel diseases: Crohn’s Disease and ulcerative colitis. In: Manojlović D, editor. Internal medicine I. Belgrade: Zavod za udžbenike i nastavna sredstva; 2006. p. 687–700. (Serbian)
Best WR, Becktel JM, Singleton JW. Rederived values of the eight coefficients of the Crohn’s Disease Activity Index (CDAI). Gastroenterology 1979; 77(4 Pt 2): 843−6.
Truelove SC, Witts LJ. Cortisone in ulcerative colitis. Final re-port on a therapeutic trial. Br Med J 1955; 2(4947): 1041–8.
Geboes K, Riddell R, Ost A, Persson T, Lofberg R. A Reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut 2000; 47(3): 404–9.
Calkins BM, Lilienfeld AM, Garland CF, Mendeloff AI. Trends in the incidence rates of ulcerative colitis and Crohn’s disease. Dig Dis Sci 1984; 29(10): 913−20.
Herrinton LJ, Liu L, Lewis JD, Griffin PM, Allison J. Incidence and Prevalence of Inflammatory Bowel Disease in a Northern California Managed Care Organization, 1996–2002. Am J Gastroenterol 2008; 103(8): 1998–2006.
Polito JM 2nd, Childs B, Mellits ED, Tokayer AZ, Harris ML, Bayless TM. Crohn's disease: Influence of age at diagnosis on site and clinical type of disease. Gastroenterol 1996; 111(3): 580–6.
Satsangi J, Morecroft J, Shah NB, Nimmo E. Genetics of inflam-matory bowel disease: scientific and clinical implications. Best Pract Res Clin Gastroenterol 2003; 17(1): 3–18.
Hendrickson BA, Gokhale R, Cho JH. Clinical aspects and pa-thophysiology of inflammatory bowel disease. Clin Microbiol Rev 2002; 15(1): 79–94.
Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, et al. Association of NOD2 leucine rich repeat variants with susceptibility to Crohn’s disease. Nature 2001; 411(6837): 599–603.
Lakatos PL, Fischer S, Lakatos L, Gal I, Papp J. Current con-cept on the pathogenesis of inflammatory bowel disease-crosstalk between genetic and microbial factors: Pathogenic bacteria and altered bacterial sensing or changes in mucosal integrity take “toll”? World J Gastroenterol 2006; 12(12): 1829–41.
Mylonaki M, Langmead L, Pantes A, Johnson F, Rampton DS. Enteric infection in relapse of inflammatory bowel disease: importance of microbiological examination of stool. Eur J Gastroenterol Hepatol 2004; 16(8): 775–8.
Meyer AM, Ramzan NN, Loftus EV Jr, Heigh RI, Leighton JA. The diagnostic yield of stool pathogen studies during relapses of inflammatory bowel disease. J Clin Gastroenterol 2004; 38(9): 772–5.
Agrawal D, Rukkannagari S, Kethu S. Pathogenesis and clinical approach to extraintestinal manifestations of inflammatory bowel disease. Minerva Gastroenterol Dietol 2007; 53(3): 233–48.
Larsen S, Bendtzen K, Nielsen OH. Extraintestinal manifesta-tions of inflammatory bowel disease: Epidemiology, diagno-sis, and management. Ann Med 2010; 42(2): 97–114.
Aghazadeh R, Zali MR, Bahari A, Amin K, Ghahghaie F, Firouzi F. Inflammatory bowel disease in Iran: a review of 457 cases. J Gastroenterol Hepatol 2005; 20(11): 1691–5.
Yüksel I, Başar O, Ataseven H, Ertuğrul I, Arhan M, Ibiş M, et al. Mucocutaneous manifestations in inflammatory bowel dis-ease. Inflamm Bowel Dis 2009; 15(4): 546–50.
Vavricka SR, Brun L, Ballabeni P, Pittet V, Vavricka BM, Zeitz J, et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol 2011; 106(1): 110–9.
Mendoza JL, Lana R, Taxonera C, Alba C, Izquierdo S, Díaz-Rubio M. Extraintestinal manifestations in inflammatory bo-wel disease: differences between Crohn’s disease and ulcera-tive colitis. Med Clin (Barc) 2005; 125(8): 297–300. (Spanish)
Meier C, Plevy S. Therapy insight: how the gut talks to the joints-inflammatory bowel disease and the spondyloarthropa-thies. Nat Clin Pract Rheumatol 2007; 3(11): 667–74.
Triantafillidis JK, Merikas E, Malgarinos G, Panteris V, Peros G. Acute idiopathic pancreatitis preceding diagnosis of Crohn’s disease. Description of three cases. Rev Med Chir Soc Med Nat Iasi 2009; 113(1): 97–102.
Rogler G, Schölmerich J. Extraintestinal manifestations of in-flammatory bowel disease. Med Klin (Munich) 2004; 99(3): 123–30. (German)